Epizyme, Inc. [NASDAQ:EPZM]: Analyst Rating and Earnings
Stock market traders frequently keep their eyes on what Wall Street experts as it relates to a potential investment. For Epizyme, Inc. [EPZM], the most recent analyst consensus recommendation available since its latest financial results for the quarter ending in December. On average, stock market experts give EPZM an Outperform rating. Its stock price has been found in the range of 10.74 to 28.62. This is compared to its latest closing price of $12.36.
Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Epizyme, Inc. [EPZM] is sitting at 1.60. This is compared to 1 month ago, when its average rating was 1.60.
Keep your eyes peeled for the soon-to-be-published financial results of this company, which are expected to be made public on Tue 12 Mar (In 27 Days).
Fundamental Analysis of Epizyme, Inc. [EPZM]
Now let’s turn to look at profitability: with a current Operating Margin for Epizyme, Inc. [EPZM] sitting at -1368.42.
This company’s Return on Total Capital is -62.50, and its Return on Invested Capital has reached -58.00%. Its Return on Equity is -61.46, and its Return on Assets is -49.58. These metrics suggest that this Epizyme, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
Turning to investigate this organization’s capital structure, Epizyme, Inc. [EPZM] has generated a Total Debt to Total Equity ratio of 0.05. Similarly, its Total Debt to Total Capital is 0.05, while its Total Debt to Total Assets stands at 0.04.
What about valuation? This company’s Enterprise Value to EBITDA is -4.93. The Enterprise Value to Sales for this firm is now 55.55, and its Total Debt to Enterprise Value stands at 0.00. Epizyme, Inc. [EPZM] has a Price to Book Ratio of 3.70.
Shifting the focus to workforce efficiency, Epizyme, Inc. [EPZM] earns $76,336 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 21.07 and its Total Asset Turnover is 0.04. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 11.59 and its Current Ratio is 11.59. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Let’s now turn our attention to trading performance: Epizyme, Inc. [EPZM] has 77.77M shares outstanding, amounting to a total market cap of $982.24M. Its stock price has been found in the range of 5.14 to 21.40. At its current price, it has moved by -40.98% from its 52-week high, and it has moved 145.72% from its 52-week low.
This stock’s Beta value is currently 3.05, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 79.74. This RSI suggests that Epizyme, Inc. is currently Overbought.
Conclusion: Is Epizyme, Inc. [EPZM] a Reliable Buy?
Shares of Epizyme, Inc. [EPZM], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.